Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization

• DOI: 10.2147/cmar.s186150
• Publication Date: 2018-12-19T18:36:26Z
• Authors: Gui-Qi Zhu; Kang Wang; Biao Wang; Yu-Jie Zhou; Yi Yang; Er-bao Chen; Zheng-jun Zhou; shao-lai zhou; Ying-hong Shi; Jian Zhou; Zhi Dai
• Keywords: Nomogram; Milan criteria

Background and aim: To investigate the value of aspartate aminotransferase-to-platelet ratio index (APRI) build a new nomogram for hepatocellular carcinoma (HCC) patients undergoing postoperative adjuvant transarterial chemoembolization (PATACE). Methods: We retrospectively reviewed 351 with HCC PATACE. collected baseline patient characteristics to obtain risk factors determining poor disease-free survival (DFS) early time recurrence (TTR) after The multivariate Cox proportional hazards model was used based on significant prognostic outcomes. Results: generated cutoff APRI as 0.50 using X-tile distinguish different outcomes in whole cohort. Two hundred seventeen high had poorer ( P <0.001) than did 134 low APRI. Furthermore, nomogram, including tumor size, alanine aminotransferase (ALT) level, white blood cell counts, Barcelona Clinic Liver Cancer grade, built DFS, while hepatitis B surface antigen, ALT, microvascular invasion, TTR. Internal validation 500 bootstrapped sample sets good concordance 0.729 DFS 0.730 Additionally, conferred more previous biomarkers. Conclusion: High associated worse shorter TTR This simple personalized data Keywords: carcinoma, index, prognosis,